Source: Annual Congress 2008 - Pulmonary vascular medicine
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. Degano, J. Le Pavec, L. Savale, X. Jais, C. Tcherakian, G. Simonneau, M. Humbert, O. Sitbon (Clamart, France). Long-term effects of bosentan in patients with human immunodeficiency virus-associated pulmonary arterial hypertension. Eur Respir J 2008; 32: Suppl. 52, 1583

Member's Comments

No comment yet.

Related content which might interest you: Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 92-98 Year: 2009 Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension Source: Eur Respir J 2004; 23: 321-326 Year: 2004 Bosentan in pulmonary arterial hypertension associated with HIV infection Source: Eur Respir J 2003; 22: Suppl. 45, 563s Year: 2003 Effect of long-term specific therapy in a cohort of 33 patients with pulmonary arterial hypertension of various etiologies Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Efficacy and safety of oral bosentan in patients with Down‘s syndrome and pulmonary arterial hypertension due to congenital heart disease Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Longer-term survival in paediatric patients with idiopathic or familial pulmonary arterial hypertension treated with bosentan Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Unique hemodynamic profile of HIV patients with portal hypertension: Comparison with HIV-associated PAH and porto-pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical diagnosis, treatment, end-points and animal models Year: 2012 Pulmonary hypertension in human immunodeficiency virus infection Source: Eur Respir J 2002; 20: Suppl. 38, 443s Year: 2002 Pulmonary arterial hypertension in patients with HIV infection Source: Eur Respir Mon 2012; 57: 82-93 Year: 2012 Long-term safety and tolerance of ambrisentan in patients with pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 205s Year: 2005 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006 Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Long-term bosentan therapy improves exercise capacity and hemodynamics in sarcoidosis-associated pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 IgG4-related disease in pulmonary arterial hypertension on long-term epoprostenol treatment Source: Eur Respir J 2014; 43: 1516-1519 Year: 2014 Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Effect of sitaxentan in patients with pulmonary arterial hypertension associated to congenital heart diseases Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018